NCT05612594View on ClinicalTrials.gov

Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Sleep Apnea
Interventions
DRUG

Bexagliflozin 20 mg

15mg once daily

DRUG

Placebo

matching placebo once daily

Trial Locations (2)

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

06520

RECRUITING

Yale New Haven Health, New Haven

All Listed Sponsors
collaborator

Case Western Reserve University

OTHER

lead

Yale University

OTHER